Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.
Authors
Nikolas Naleid
Department of Internal Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH
Nikolas Naleid , Veronica Mears , Hanna Kakish , Amit Mahipal , Sakti Chakrabarti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 744)
DOI
10.1200/JCO.2024.42.3_suppl.744
Abstract #
744
Poster Bd #
L19
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.
First Author: Peter Zang
Poster
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
First Author: Minal A. Barve
Poster
2024 ASCO Annual Meeting
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.
First Author: Daneng Li
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.
First Author: Daneng Li